Literature DB >> 22688931

Breathless on bortezomib.

Devaki O'Riordan1, John Houghton, Roger Chisholm, B Ronan O'Driscoll.   

Abstract

The authors describe a case of episodic acute pneumonitis occurring after repeated doses of bortezomib, a drug being used increasingly to treat multiple myeloma. The delay in presentation each time with fever, dyspnoea, hypoxia and interstitial radiological changes contributed to under-recognition of this complication, which has so far been described in only a handful of patients, but the pattern seen may offer clues to pathogenesis and potential treatments. This case highlights the need for both physicians and patients consenting to bortezomib treatment to be more aware of this potentially fatal adverse effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22688931      PMCID: PMC3171048          DOI: 10.1136/bcr.03.2011.4028

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Severe pulmonary complication after bortezomib treatment for multiple myeloma.

Authors:  James E Boyer; Reema B Batra; Joao L Ascensao; Geraldine P Schechter
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

2.  Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.

Authors:  Patrizia Zappasodi; Roberto Dore; Carlo Castagnola; Cesare Astori; Marzia Varettoni; Silvia Mangiacavalli; Mario Lazzarino; Alessandro Corso
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

3.  Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

Authors:  Shigesaburo Miyakoshi; Masahiro Kami; Koichiro Yuji; Tomoko Matsumura; Masaaki Takatoku; Makoto Sasaki; Hiroto Narimatsu; Takeshi Fujii; Masateru Kawabata; Shuichi Taniguchi; Keiya Ozawa; Kazuo Oshimi
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

4.  Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.

Authors:  Wonseok Kang; Jin Seok Kim; Sang Ho Cho; Sung Kyu Kim; Joon Chang; Moo Suk Park
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

5.  United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Authors:  Robert C Kane; Ann T Farrell; Rajeshwari Sridhara; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

6.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

7.  A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease.

Authors:  V A Varney; H M Parnell; D T Salisbury; S Ratnatheepan; R B Tayar
Journal:  Pulm Pharmacol Ther       Date:  2007-02-27       Impact factor: 3.410

  7 in total
  1 in total

Review 1.  Immunotherapy for Refractory Autoimmune Encephalitis.

Authors:  Jiawei Yang; Xueyan Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.